Zhang, Xindan
Zhao, Zhenggang
Wang, Xuepeng
Zhang, Shiwei
Zhao, Zilong
Feng, Wenbin
Xu, Lijun
Nie, Junhua
Li, Hong
Liu, Jia
Xiao, Gengmiao
Zhang, Yu
Li, Haomiao
Lu, Ming
Mai, Jialuo
Zhou, Sujin
Zhao, Allan Z. http://orcid.org/0000-0003-2136-0972
Li, Fanghong
Article History
Received: 6 January 2024
Revised: 26 April 2024
Accepted: 7 May 2024
First Online: 20 May 2024
Competing interests
: AZZ is a shareholder of Guangzhou Sinogen Pharmaceutical. We confirm that all authors have seen and approved the final version of the manuscript being submitted. All authors warrant that the article is the original work, hasn’t received prior publication, and isn’t under consideration for publication elsewhere.
: All experiments were conducted with protocols approved by Laboratory Animal Center of Guang Dong Pharmaceutical University (Guangzhou, PR China). Animal care procedures strictly follow the animal care guidelines formulated by the animal care committee of Guangdong Pharmaceutical University (Guangzhou, PR China, Ethics permit number: gdpulacspf2017064).